For instance, a trial called CheckMate-143 compared nivolumab (anti-PD-1) and bevacizumab in recurrent GBM patients, but there was no significant difference in overall survival (OS) between the two treatments [11,17,18]. Here, PDCD1 is linked to glioblastoma.